The LMCD1 (LIM and Cysteine-Rich Domains 1) antibody is a tool used to detect the LMCD1 protein, a member of the LIM domain-containing protein family. LMCD1 is characterized by two LIM domains, which mediate protein-protein interactions, and a conserved cysteine-rich region. It functions as a transcriptional co-regulator, interacting with factors like GATA6 to modulate gene expression involved in cellular processes such as differentiation, proliferation, and apoptosis. LMCD1 is implicated in various physiological and pathological contexts, including cardiovascular development, skeletal muscle regeneration, and fibrosis. Dysregulation of LMCD1 has been linked to diseases such as pulmonary arterial hypertension, liver fibrosis, and cancers (e.g., lung and hepatocellular carcinoma), where it may act as either a tumor suppressor or oncogene depending on context. The LMCD1 antibody is widely utilized in research applications like Western blotting, immunohistochemistry, and immunofluorescence to study LMCD1's expression, localization, and mechanistic roles in disease models. Both polyclonal and monoclonal variants exist, with specificity validated through techniques like knockout cell line controls. Its development has advanced understanding of LMCD1's dual roles in tissue homeostasis and disease progression, highlighting potential therapeutic targets.